Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the a...

書誌詳細
主要な著者:	Mease, P, Kavanaugh, A, Coates, L, McInnes, I, Hojnik, M, Zhang, Y, Anderson, J, Dorr, A, Gladman, D
フォーマット:	Journal article
言語:	English
出版事項:	BMJ Publishing Group 2017

類似資料

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
著者:: Coates, L, 等
出版事項: (2019)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
著者:: Kavanaugh, A, 等
出版事項: (2024)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
著者:: Gladman, DD, 等
出版事項: (2018)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
著者:: Mease, PJ, 等
出版事項: (2020)

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
著者:: Choy, E, 等
出版事項: (2007)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
著者:: Coates, LC, 等
出版事項: (2021)

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
著者:: Kavanaugh, A, 等
出版事項: (2005)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
著者:: Coates, LC, 等
出版事項: (2024)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
著者:: Landewé, R, 等
出版事項: (2019)

Psoriatic arthritis
著者:: FitzGerald, O, 等
出版事項: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
著者:: Ogdie, A, 等
出版事項: (2023)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
著者:: Désirée van der Heijde, 等
出版事項: (2020-02-01)

Classification and outcome measures for psoriatic arthritis
著者:: Leung, Y, 等
出版事項: (2018)

Measuring outcomes in psoriatic arthritis
著者:: Ogdie, A, 等
出版事項: (2020)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
著者:: Laura C. Coates, 等
出版事項: (2024-02-01)

Considerations for the definition of remission criteria in psoriatic arthritis
著者:: Mease, P, 等
出版事項: (2017)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
著者:: Orbai, A-M, 等
出版事項: (2019)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
著者:: Alexis Ogdie, 等
出版事項: (2023-05-01)

Assessing disease activity in psoriatic arthritis: a literature review
著者:: Tucker, L, 等
出版事項: (2018)

Classification and Outcome Measures for Psoriatic Arthritis
著者:: Ying Ying Leung, 等
出版事項: (2018-09-01)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
著者:: Soriano, ER, 等
出版事項: (2023)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
著者:: Coates, L, 等
出版事項: (2017)

Residual inflammation in psoriatic arthritis patients in stable minimal disease activity
著者:: Pierluigi Macchioni, 等
出版事項: (2022-12-01)

Methotrexate in psoriasis and psoriatic arthritis
著者:: Coates, L, 等
出版事項: (2020)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
著者:: Helliwell, PS, 等
出版事項: (2022)

Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity
著者:: Ye, W, 等
出版事項: (2018)

Sustained very low disease activity and remission in psoriatic arthritis patients
著者:: Lubrano, E, 等
出版事項: (2019)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
著者:: Yazji, SM, 等
出版事項: (2025)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
著者:: Strand, V, 等
出版事項: (2022)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
著者:: Ennio Lubrano, 等
出版事項: (2019-08-01)

Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
著者:: Silvia Scriffignano, 等
出版事項: (2023-09-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
著者:: Coates, L, 等
出版事項: (2021)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
著者:: Coates, L, 等
出版事項: (2018)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
著者:: Mease, PJ, 等
出版事項: (2019)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
著者:: Atul Deodhar, 等
出版事項: (2022-07-01)

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
著者:: Coates, L, 等
出版事項: (2018)

Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study
著者:: Rubén Queiro, 等
出版事項: (2017-03-01)

BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS
著者:: D.D. Gladman
出版事項: (2011-09-01)

Duration of Psoriatic Skin Disease as Risk Factor for Subsequent Onset of Psoriatic Arthritis
著者:: Alexander Egeberg, 等
出版事項: (2018-03-01)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
著者:: Laura C. Coates, 等
出版事項: (2018-08-01)